Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Gold ETFs EXPLODE: India's Gold Investment Crosses ₹1 Lakh Crore - Is This Your Next Big Opportunity?

Commodities

|

Updated on 11 Nov 2025, 03:03 pm

Whalesbook Logo

Reviewed By

Akshat Lakshkar | Whalesbook News Team

Short Description:

Gold Exchange Traded Funds (ETFs) in India have reached a historic milestone, with total assets under management (AUM) soaring to over ₹1 lakh crore for the first time. Investors continued their strong appetite for gold ETFs in October, adding ₹7,743 crore, following a record ₹8,363 crore in September. This sustained inflow indicates unwavering investor confidence in gold as a key asset, even as prices remain high.
Gold ETFs EXPLODE: India's Gold Investment Crosses ₹1 Lakh Crore - Is This Your Next Big Opportunity?

▶

Detailed Coverage:

Gold Exchange Traded Funds (ETFs) in India have achieved a significant landmark, crossing ₹1 lakh crore in total Assets Under Management (AUM) for the first time. As of October 31, 2025, the total AUM stood at an impressive ₹1,02,120 crore. This milestone highlights the growing popularity of gold ETFs as a preferred investment vehicle among Indian investors.

In October alone, Indian investors poured ₹7,743 crore into gold ETFs, marking the sixth consecutive month of net inflows. This follows a record inflow of ₹8,363 crore in September, demonstrating sustained enthusiasm for the asset class. Despite the high gold prices, with the average spot rate on MCX reaching ₹1,22,465 per 10 grams in October (a 5% increase from the previous month), investors have largely refrained from booking profits, signaling strong conviction.

Bullion ETFs are passive investment funds designed to track the price of gold. They offer a convenient, tax-efficient, and proxy way for investors to gain exposure to gold without the need for physical storage. Over 20 such funds are available in India.

Impact This news indicates a strong preference among Indian investors for gold as a safe-haven asset and a hedge against inflation and market volatility. The substantial inflows suggest a potential shift in asset allocation and a robust demand for precious metals, which can influence broader market sentiment and investment trends. It also reflects a maturing investment landscape in India with greater adoption of diverse investment instruments. Rating: 7/10

Difficult Terms Explained: Bullion ETFs: Exchange Traded Funds that invest in physical gold or gold futures contracts, tracking the price of the precious metal. AUM (Assets Under Management): The total market value of all the investments held by a fund. It represents the total amount of money clients have invested in that fund. MCX (Multi Commodity Exchange): India's first independent commodity futures exchange where trading takes place for various commodities including gold and silver.


Other Sector

RVNL's Q2 Shock: Profits Plummet, But Revenue Inches Up! What Investors Need to Know NOW!

RVNL's Q2 Shock: Profits Plummet, But Revenue Inches Up! What Investors Need to Know NOW!

RVNL's Q2 Shock: Profits Plummet, But Revenue Inches Up! What Investors Need to Know NOW!

RVNL's Q2 Shock: Profits Plummet, But Revenue Inches Up! What Investors Need to Know NOW!


Healthcare/Biotech Sector

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Biocon's Q2 FY26 Triumph: Revenue Soars 20%, Biosimilars Lead Explosive Growth!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Wegovy Price SHOCK: Novo Nordisk Slashes India Costs Up to 37%! Diabetes & Obesity Drug Now More Affordable!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Motilal Oswal REITERATES BUY on Mankind Pharma: Rs 2800 Target & Growth Outlook Revealed!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

Medikabazaar's Jaw-Dropping Comeback: From Heavy Losses to Record Profits and Global Ambitions!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

India's Pharma Powerhouse Cracks China: Massive Diabetes Drug Deals Signed!

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?

Wegovy Price CRASHED 37% in India! Novo Nordisk's Bold Move to Win Obesity Market?